Table 3 Skin status at one-year follow-up examination
IM IFNβ-1a (n = 73) | SC IFNβ-1b (n = 104) | SC IFNβ-1a (n = 154) | SC GA (n = 14) | Overall (N = 345) | |
|---|---|---|---|---|---|
Necrosis, n (%) | 0 (0) | 5 (4.8) | 5 (3.2) | 0 (0) | 10 (2.9) |
Number of occurrences | |||||
1 | 0 | 3/5 (60.0) | 2/5 (40.0) | 0 | 5/10 (50.0) |
2 | 0 | 1/5 (20.0) | 2/5 (40.0) | 0 | 3/10 (30.0) |
Unknown | 0 | 1/5 (20.0) | 1/5 (20.0) | 0 | 2/10 (20.0) |
Severity | |||||
Mild | 0 | 3/5 (60.0) | 1/5 (20.0) | 0 | 4/10 (40.0) |
Moderate | 0 | 0 | 3/5 (60.0) | 0 | 3/10 (30.0) |
Severe | 0 | 1/5 (20.0) | 0 | 0 | 1/10 (10.0) |
Unknown | 0 | 1/5 (20.0) | 1/5 (20.0) | 0 | 2/10 (20.0) |
Lipoatrophy, n (%) | 0 (0)a | 9 (8.7) | 23 (15.0)b | 1 (7.1) | 33 (9.6) |
Number of occurrences | |||||
1 | 0 | 3/9 (33.3) | 4/23 (17.4) | 0 | 7/33 (21.2) |
2 | 0 | 2/9 (22.2) | 11/23 (47.8) | 1/1 (100) | 14/33 (42.4) |
3 | 0 | 3/9 (33.3) | 3/23 (13.0) | 0 | 6/33 (18.2) |
4 | 0 | 0 | 1/23 (4.3) | 0 | 1/33 (3.0) |
≥5 | 0 | 1/9 (11.1) | 3/23 (13.0) | 0 | 4/33 (12.1) |
Unknown | 0 | 0 | 1/23 (4.3) | 0 | 1/33 (3.0) |
Severity | |||||
Mild | 0 | 6/9 (66.7) | 11/23 (47.8) | 0 | 17/33 (51.5) |
Moderate | 0 | 2/9 (22.2) | 6/23 (26.1) | 1/1 (100) | 9/33 (27.3) |
Severe | 0 | 1/9 (11.1) | 1/23 (4.3) | 0 | 2/33 (6.1) |
Unknown | 0 | 0 | 5/23 (21.7) | 0 | 5/33 (15.2) |